MedTrace Logo

Comparison of Positive Psychotherapy and Cognitive-Behavioral Psychotherapy for Depression

NCT02572921 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-10-09

No results posted yet for this study

Summary

This study evaluates the effects of the Positive Psychotherapy on depressive symptoms and on happiness compared with regular cognitive behavioral therapy.

Conditions

Interventions

BEHAVIORAL

Positive Psychotherapy

The Positive Psychotherapy Group Treatment was developed by Martin Seligman and Tayyab Rashid (2013) and consists of 14 weekly group sessions of 2 hours. The strictly manualized program includes the following components: positive orientation and introduction, character strengths, signature strengths, good vs. bad memories, forgiveness, gratitude, satisficing vs. maximising, meaningful life, posttraumatic growth, hope and optimism, positive communication, signature strengths of others, savouring and slowness, altruism and the last session is about the integration of all these components to the "full life".

BEHAVIORAL

Cognitive behavioral therapy

This well-established, cognitive-behavior group therapy was developed by Schaub, Roth and Goldmann (2006) and consists of 12 weekly group sessions of 2 hours. The strictly manualized program includes the following components: education, building up activities, cognitive restructuring, relapse prevention. Moreover, there are 2 sessions added to the standard program: one session concerning savouring and the other one concerning stress reduction. Thus the whole program consists of 14 sessions.

Sponsors & Collaborators

  • The Wagner-Jauregg Provincial Neuropsychiatric Clinic

    collaborator INDIV

  • University of Salzburg

    lead OTHER

Principal Investigators

  • Anton-Rupert Laireiter, Univ.-Prof.Dr. · Paris Lodron University of Salzburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-05-31
Completion
2016-07-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02572921 on ClinicalTrials.gov